Case Discussion: 68-Year-Old With R/R Follicular Lymphoma
A panel of hematologist-oncologists share best practices for managing a 68-year-old male with relapsed/refractory follicular lymphoma who is under consideration for treatment with tazemetostat.
R/R Follicular Lymphoma: Testing for EZH2
Andrew M. Evens, DO, MSc, FACP, of Rutgers Cancer Institute of New Jersey, comments on the rationale for testing for EZH2 mutations in relapsed/refractory follicular lymphoma.
Evolving Therapies in R/R DLBCL: Concluding Remarks
R/R DLBCL: A Glance at Using Novel Therapies Moving Forward
R/R DLBCL: Novel Therapies in the Pipeline
EZH2 Inhibition in R/R FL: Safety & Efficacy Data
Takeaways of safety and efficacy data published on tazemetostat, an EZH2 inhibitor, to treat relapsed/refractory follicular lymphoma, and implications for using the drug in clinical practice.
Tazemetostat for R/R Follicular Lymphoma
Drs Andrew M. Evens and Loretta J. Nastoupil remark on the recent approval of tazemetostat, an EZH2 inhibitor, as treatment for relapsed/refractory follicular lymphoma and highlight which types of patients are most appropriate to manage with this drug.
Treating Primary Refractory DLBCL
Bridging Therapy in R/R DLBCL
R2 Regimen for R/R Follicular Lymphoma
An overview of the MAGNIFY data and implications for treating appropriate patients with relapsed/refractory follicular lymphoma with the R2 regimen.
PI3K Inhibitors for R/R Follicular Lymphoma
Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.
R/R DLBCL: Transplants in the Era of CAR-T
CAR T for R/R DLBCL: Improving Access and Utilization
R/R Follicular Lymphoma: Third-Line Treatment Options
Currently available third-line treatment options for relapsed/refractory follicular lymphoma and unique considerations when selecting an appropriate therapy in this setting.
Transplantation for R/R Follicular Lymphoma
The rationale for treating patients with relapsed/refractory follicular lymphoma with allogeneic or autologous transplantation in the current era of novel therapies.
CAR T for R/R DLBCL: Safety/Tolerability
Understanding the CAR-T Process: Collection Through Infusion
MRD Testing in R/R Follicular Lymphoma
Drs Caron A. Jacobson and Krish Patel comment on NGS (next-generation sequencing) and MRD (minimal residual disease) testing in relapsed/refractory follicular lymphoma.
Role of Rebiopsy in R/R Follicular Lymphoma
The rationale for rebiopsying patients who have relapsed/refractory follicular lymphoma and the types of molecular information that can be applied to treatment decisions.
Treating R/R DLBCL With CAR-T: Current Barriers
CAR-T Treatment Options for R/R DLBCL
R/R Follicular Lymphoma: Second-line Treatment Selection
Factors that hematologist-oncologists need to consider when selecting second-line therapy for relapsed follicular lymphoma.
R/R Follicular Lymphoma: Patient Prognosis
Insight regarding the prognosis for patients with follicular lymphoma who relapse and impact of treatment sequencing on this trajectory.
CAR T-Cell Therapy for R/R DLBCL
Novel Therapies for R/R DLBCL
R/R DLBCL: Treating With Tafasitamab-Lenalidomide
Tafasitamab Combined With Lenalidomide in R/R DLBCL
R/R DLBCL: Second-Line Treatment Options
DLBCL: Treating Patients Following Relapse on Frontline Therapy
DLBCL: Treatment Considerations for Challenging Populations
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512